It took about 20 years of preclinical research to begin the first phase of prophylactic trials.
The development targets a protein commonly expressed by triple negative breast cancer. The latter is a subtype of breast cancer. It accounts for 15% of all cancers.
Triple negative breast cancer is calledso, because it lacks one of three basic molecular characteristics: that is what modern therapies usually target. This means that triple negative breast cancer is especially dangerous.
Previously, scientists found that breast cancer cellsglands often express high levels of a protein called α-lactalbumin. In particular, it has been found that triple negative breast cancer cells typically express a protein. From this characteristic, it is easy to make a targeted vaccine.
The general idea behind the vaccine is that α-lactalbumin can be a so-called immunological target - we can stimulate the immune system to attack the cells that make this protein.
Omas Budd, Principal Investigator
Animal tests have confirmed this theory. The authors will now test their drug in humans and test the vaccine's safety profile as well as assess the immunological responses.
According to experts, there are at least ten years left before the vaccine is used clinically, and this is provided that each stage of research is perfect.
Hubble took a photo of the same active galaxy 20 years apart
Astronomers told where and how gold and platinum are formed in the universe
Hear the sounds of Mars recorded by the Perseverance mission